File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Evaluating the Safety and effectiveness in adult Korean patients treated with Tolvaptan for management of autosomal dominant polycystic kidney disease (ESSENTIAL): short-term outcomes during the titration period

TitleEvaluating the Safety and effectiveness in adult Korean patients treated with Tolvaptan for management of autosomal dominant polycystic kidney disease (ESSENTIAL): short-term outcomes during the titration period
Authors
KeywordsClinical trial phase IV
Polycystic kidney autosomal dominant
Tolvaptan
Issue Date1-Mar-2023
PublisherElsevier / Korean Society of Nephrology
Citation
Kidney Research and Clinical Practice, 2023, v. 42, n. 2, p. 216-228 How to Cite?
Abstract

Background: Tolvaptan reduces height-adjusted total kidney volume (htTKV) and renal function decline in autosomal dominant polycystic kidney disease (ADPKD). This study was aimed at investigating the efficacy and safety of tolvaptan in Korean patients with ADPKD during the titration period.

Methods: This study is a multicenter, single-arm, open-label phase 4 study. We enrolled 108 patients with ADPKD (age, 19-50 years) with an estimated glomerular filtration rate (eGFR) of >30 mL/min/1.73 m2 and factors defined as indicative of rapid disease progression. After tolvaptan titration, we evaluated efficacy and side effects and assessed factors associated with the effects.

Results: After titration for 4 weeks, eGFR and htTKV decreased by 6.4 ± 7.9 mL/min/1.73 m2 and 16 ± 45 mL/m, respectively. No serious adverse drug reactions were observed during the titration period. The greatest eGFR decline was observed in the first week, with a starting tolvaptan dose of 45 mg. Multivariate linear regression for htTKV decline showed that the greater the change in urine osmolality (Uosm), the greater the decrease in htTKV (β, 0.436; p = 0.009) in the 1D group stratified by the Mayo Clinic image classification. Higher baseline eGFR was related to a higher htTKV reduction rate in the 1E group (β, -0.642; p = 0.009).

Conclusion: We observed short-term effects and safety during the tolvaptan titration period. The decline of htTKV can be predicted as a short-term effect of tolvaptan by observing Uosm changes from baseline to end of titration in 1D and baseline eGFR in 1E groups.


Persistent Identifierhttp://hdl.handle.net/10722/331049
ISSN
2023 Impact Factor: 2.9
2023 SCImago Journal Rankings: 0.820
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorHuh, H-
dc.contributor.authorKim, YS-
dc.contributor.authorChung, W-
dc.contributor.authorKim, YL-
dc.contributor.authorKim, Y-
dc.contributor.authorHan, S-
dc.contributor.authorJung, Y-
dc.contributor.authorNa, KY-
dc.contributor.authorLee, KB-
dc.contributor.authorOh, YK-
dc.contributor.authorPark, HC-
dc.contributor.authorHan, SH-
dc.contributor.authorYoo, TH-
dc.contributor.authorKim, YH-
dc.contributor.authorKim, SW-
dc.contributor.authorLee, KW-
dc.contributor.authorPark, HC-
dc.contributor.authorKim, SG-
dc.contributor.authorKim, H-
dc.contributor.authorLee, CH-
dc.contributor.authorBae, KT-
dc.contributor.authorOh, KH-
dc.contributor.authorAhn, C-
dc.contributor.authorRyu, HJ-
dc.contributor.authorKim, YC -
dc.date.accessioned2023-09-21T06:52:20Z-
dc.date.available2023-09-21T06:52:20Z-
dc.date.issued2023-03-01-
dc.identifier.citationKidney Research and Clinical Practice, 2023, v. 42, n. 2, p. 216-228-
dc.identifier.issn2211-9132-
dc.identifier.urihttp://hdl.handle.net/10722/331049-
dc.description.abstract<p><strong>Background: </strong>Tolvaptan reduces height-adjusted total kidney volume (htTKV) and renal function decline in autosomal dominant polycystic kidney disease (ADPKD). This study was aimed at investigating the efficacy and safety of tolvaptan in Korean patients with ADPKD during the titration period.</p><p><strong>Methods: </strong>This study is a multicenter, single-arm, open-label phase 4 study. We enrolled 108 patients with ADPKD (age, 19-50 years) with an estimated glomerular filtration rate (eGFR) of >30 mL/min/1.73 m2 and factors defined as indicative of rapid disease progression. After tolvaptan titration, we evaluated efficacy and side effects and assessed factors associated with the effects.</p><p><strong>Results: </strong>After titration for 4 weeks, eGFR and htTKV decreased by 6.4 ± 7.9 mL/min/1.73 m2 and 16 ± 45 mL/m, respectively. No serious adverse drug reactions were observed during the titration period. The greatest eGFR decline was observed in the first week, with a starting tolvaptan dose of 45 mg. Multivariate linear regression for htTKV decline showed that the greater the change in urine osmolality (Uosm), the greater the decrease in htTKV (β, 0.436; p = 0.009) in the 1D group stratified by the Mayo Clinic image classification. Higher baseline eGFR was related to a higher htTKV reduction rate in the 1E group (β, -0.642; p = 0.009).</p><p><strong>Conclusion: </strong>We observed short-term effects and safety during the tolvaptan titration period. The decline of htTKV can be predicted as a short-term effect of tolvaptan by observing Uosm changes from baseline to end of titration in 1D and baseline eGFR in 1E groups.</p>-
dc.languageeng-
dc.publisherElsevier / Korean Society of Nephrology-
dc.relation.ispartofKidney Research and Clinical Practice-
dc.rightsThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.-
dc.subjectClinical trial phase IV-
dc.subjectPolycystic kidney autosomal dominant-
dc.subjectTolvaptan-
dc.titleEvaluating the Safety and effectiveness in adult Korean patients treated with Tolvaptan for management of autosomal dominant polycystic kidney disease (ESSENTIAL): short-term outcomes during the titration period-
dc.typeArticle-
dc.identifier.doi10.23876/j.krcp.22.024-
dc.identifier.scopuseid_2-s2.0-85164260192-
dc.identifier.volume42-
dc.identifier.issue2-
dc.identifier.spage216-
dc.identifier.epage228-
dc.identifier.isiWOS:000974142000005-
dc.identifier.issnl2211-9132-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats